Exelixis files new patent infringement suit against MSN over generic CABOMETYX

EXELIXIS, INC.

Filed complaint in Delaware asserting infringement of three new patents (11,091,439; 11,091,440; 11,098,015) related to cabozantinib.
MSN amended its ANDA for generic CABOMETYX tablets (20/40/60 mg); Exelixis seeks injunction and approval date no earlier than patent expiration (latest Jan 15, 2030).
This new case is separate from the 2019/2020 MSN ANDA Actions, which are scheduled for trial in May 2022.
Exelixis also seeks order that FDA approval of MSN's ANDA be delayed until after patent expirations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.